Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib in EGFR-mutated Metastatic NSCLC With Brain Metastases After EGFR TKI Failure
NCT05326425Phase 2Unknown
- Start
- Jun 2021
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of lazertinib in non-small cell lung cancer (NSCLC). Status: unknown.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05326425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05326425.